VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS10046482 | HBV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
TVIS10057601 | HBV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
TVIS30021024 | HIV | ENSG00000010671.18 | protein_coding | BTK | Yes | No | 695 | Q06187 Q5JY90 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | BTK |
---|---|
DrugBank ID | DB12010 |
Drug Name | Fostamatinib |
Target ID | BE0001284 |
UniProt ID | Q06187 |
Regulation Type | inhibitor |
PubMed IDs | 26516587; 34209188 |
Citations | Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.@@Kaliamurthi S, Selvaraj G, Selvaraj C, Singh SK, Wei DQ, Peslherbe GH: Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19. Int J Mol Sci. 2021 Jun 30;22(13). pii: ijms22137071. doi: 10.3390/ijms22137071. |
Groups | Approved; Investigational |
Direct Classification | Methoxyanilines |
SMILES | COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC |
Pathways | |
PharmGKB | |
ChEMBL | CHEMBL2103830 |